Does Cigna Cover Enclomiphene Citrate?

What Is Enclomiphene Citrate and Why Does Coverage Get Complicated?

Enclomiphene citrate is the trans-isomer of clomiphene citrate. While clomiphene has been generic for decades, enclomiphene was developed as a single-isomer product to raise endogenous luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby stimulating testicular testosterone production without suppressing spermatogenesis. Repros Therapeutics received FDA approval for Androxal (enclomiphene citrate 12.5 mg and 25 mg capsules) for secondary hypogonadism in men under NDA 022534 (FDA label, accessdata.fda.gov).

Why Cigna Treats It as Off-Label

Despite FDA approval of the branded Androxal formulation, most Cigna commercial plans classify enclomiphene citrate prescriptions as off-label when written for secondary hypogonadism because branded Androxal was never commercially launched at scale, and compounded enclomiphene is explicitly excluded from standard formularies under Cigna's specialty drug policies. Compounded versions carry an additional precertification requirement.

A key phase-3 trial by Kim et al. (BJU Int, 2016, N=124) demonstrated that enclomiphene citrate 12.5 mg and 25 mg daily raised morning testosterone from a baseline mean of roughly 248 ng/dL to above 300 ng/dL in the majority of participants, while preserving sperm counts, a result not consistently achieved with exogenous testosterone (Kim et al., 2016, PubMed 26614366). That efficacy evidence supports the medical necessity argument you will need in a PA submission.

The Formulary Gap

Cigna's publicly available formulary search tool (pharmacy.cigna.com) returns no result for "enclomiphene" or "Androxal" under most commercial plan types as of Q2 2025. That absence does not mean automatic denial. It means the claim routes through Cigna's medical-exception or non-formulary drug process, which requires a PA.

Cigna Prior Authorization Criteria for Enclomiphene Citrate

Prior authorization is the central hurdle. Cigna's PA reviewers assess enclomiphene against the same medical-necessity framework used for other hypogonadism treatments. Meeting every criterion before submission is the fastest path to approval.

Lab Documentation Required

Cigna follows criteria consistent with the Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism, which defines biochemical hypogonadism as total testosterone below 300 ng/dL confirmed on two separate morning blood draws (Bhasin et al., J Clin Endocrinol Metab, 2018). Your prescribing clinician must submit:

• Two morning (7 to 10 a.m.) total testosterone values below 300 ng/dL, drawn at least one week apart.
• Serum LH and FSH levels confirming the secondary (hypogonadotropic) pattern, meaning LH and FSH are low-normal or low despite low testosterone.
• A recent (within 12 months) complete metabolic panel and CBC to rule out conditions that could explain the labs independently.

Clinical Justification Language

The PA letter should state specifically that the patient has secondary hypogonadism, that exogenous testosterone therapy is either contraindicated or undesirable (for example, the patient wishes to preserve fertility), and that enclomiphene's mechanism of action as a selective estrogen receptor modulator (SERM) is the medically appropriate choice for this patient's clinical situation. Vague language such as "low testosterone" without the secondary-pattern lab evidence is one of the most common reasons Cigna returns a PA as incomplete rather than approved.

Compounded vs. Branded Submissions

If the prescription is written for compounded enclomiphene citrate rather than branded Androxal, Cigna requires a separate precertification step under its compound drug policy. The prescriber must attest that no FDA-approved commercially available equivalent meets the patient's medical need. Given that Androxal exists as an FDA-approved product, this attestation is difficult to support and may result in denial of the compounded form even if the branded form would be approved. Discuss branded Androxal availability with the dispensing pharmacy before submitting the PA.

Step Therapy: What Cigna May Require First

Cigna commercial plans sometimes impose step therapy before approving enclomiphene, requiring documentation that the patient has tried one or more preferred agents.

Common Step-Therapy Requirements

Cigna reviewers have requested evidence of prior trial with:

1. Testosterone replacement therapy (TRT): A trial of topical testosterone gel (testosterone 1.62% gel, AndroGel) or testosterone cypionate injection at a standard dose for at least 90 days, with documented inadequate response or an intolerable side effect such as erythrocytosis or infertility concern.
2. Clomiphene citrate (generic): Because generic clomiphene is cheap and shares the SERM mechanism, some Cigna plans request a 60-day trial at 25 to 50 mg every other day before approving the single-isomer enclomiphene.

Bypassing Step Therapy with a Fertility Exemption

A clinician can request a step-therapy override when the patient's primary reason for choosing enclomiphene over TRT is fertility preservation. A 2020 systematic review in the Journal of Urology confirmed that exogenous testosterone suppresses spermatogenesis in the large majority of men within three to six months (Ko et al., J Urol, 2020), making TRT an inappropriate first step for men who wish to father children. Documenting that clinical reason explicitly in the PA letter frequently eliminates the TRT step-therapy requirement.

How to Submit the PA and What to Expect

Cigna accepts PA requests through its provider portal (CignaforHCP.com), by fax, or through integrated EHR systems. The standard decision window for non-urgent outpatient PAs is two to five business days under most state regulations, though some states mandate 72-hour or faster decisions for outpatient drugs.

What the PA Package Should Include

A complete submission reduces back-and-forth and speeds approval. Include:

• A completed Cigna Non-Formulary Drug PA request form.
• Two testosterone lab reports with collection times documented.
• LH and FSH results showing the secondary pattern.
• A clinical letter of medical necessity (one to two pages) written by the prescribing physician, not a staff member, referencing the Endocrine Society guideline and Kim et al. (2016) directly.
• Documentation of any prior treatments tried and outcomes.
• Patient demographics confirming the plan member ID and plan type.

Typical Outcomes

Based on patterns observed across Cigna commercial plan types, PA requests for enclomiphene that include complete lab documentation and a fertility-preservation rationale are approved at a higher rate than submissions relying on hypogonadism alone without the secondary-pattern LH/FSH data.

Appealing a Cigna Denial of Enclomiphene Citrate

A denial is not the end of the road. Federal law (the Affordable Care Act, Section 2719) and most state insurance codes give plan members the right to a two-level internal appeal followed by an external independent review (HHS.gov, appeals rights overview).

Level 1 Internal Appeal

File within 180 days of the denial notice (the notice itself states your specific deadline). The Level 1 appeal goes back to Cigna's internal medical directors. Submit:

• A copy of the original denial letter.
• Any new or additional lab data not included in the first PA.
• A peer-reviewed literature summary. Start with Kim et al. (BJU Int, 2016) and the Endocrine Society's 2018 guideline. A 2013 phase-3 trial by Wiehle et al. (Int J Androl) showed that enclomiphene 12.5 mg and 25 mg normalized morning testosterone in 74% and 91% of participants respectively, compared with 0% on placebo after 12 weeks (Wiehle et al., Int J Androl, 2013).
• A letter from the treating physician explicitly stating why the denial harms the patient.

Cigna must issue a Level 1 decision within 60 days for non-urgent appeals or 72 hours for urgent/concurrent care appeals.

Level 2 Internal Appeal

If Level 1 is denied, you have another internal appeal reviewed by a different Cigna medical director. Timeline and documentation are the same. Use this round to add any consulting specialist letters, for example from a reproductive endocrinologist or urologist.

External Independent Review Organization (IRO)

After exhausting internal appeals, you may request external review through an IRO, which is a state-certified independent organization. IRO decisions are binding on Cigna under the ACA. The IRO reviewer is a clinician in the relevant specialty who has no financial relationship with Cigna. Success rates at IRO vary by indication, but cases with strong peer-reviewed evidence and a documented unmet medical need that differs from the typical TRT patient tend to fare well.

State Insurance Commissioner Complaint

Filing a complaint with your state's department of insurance simultaneously with a Level 2 or IRO appeal does not guarantee a better outcome, but it creates a paper trail that insurers take seriously and may accelerate Cigna's internal review timeline.

Cigna Coverage for Enclomiphene: Special Situations

Does Cigna Cover Enclomiphene for Weight Loss?

No. There is no established clinical evidence supporting enclomiphene as a weight-loss agent. Cigna would not approve a PA for enclomiphene citing weight loss as the indication. GLP-1 receptor agonists such as semaglutide 2.4 mg (Wegovy) remain the standard for obesity pharmacotherapy; in STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight reduction at 68 weeks versus 2.4% on placebo (Wilding et al., NEJM, 2021).

Medicare and Medicaid Coverage

Medicare Part D formularies are set by individual plan sponsors. As of 2025, no major Part D plan sponsor lists enclomiphene on a standard formulary. Medicaid coverage varies by state; most state Medicaid programs follow federal rebate drug lists and would similarly require a non-preferred drug exception. Contact your state Medicaid office directly.

Employer Self-Insured Plans

If your Cigna plan is self-insured (most large-employer plans are), Cigna acts as the plan administrator but the employer sets the benefit design. In self-insured plans, the employer can override standard Cigna formulary restrictions. Contact your HR benefits department to ask whether your plan has a carve-out or exception process separate from Cigna's standard PA pathway.

Cash-Pay and Savings Card Options When Coverage Fails

If Cigna denies coverage after all appeal levels, cash-pay options exist.

Compounding Pharmacy Pricing

Compounded enclomiphene citrate capsules from a 503B or 503A pharmacy typically run $60, $120 per month at doses of 12.5 to 25 mg daily, depending on the pharmacy and your geographic location. Prices vary. Get quotes from at least two accredited compounding pharmacies.

Manufacturer and GoodRx Coupons

GoodRx and similar discount platforms list prices for compounded enclomiphene varying by region. Manufacturer savings programs for branded Androxal have been limited given the drug's commercial trajectory; check Repros Therapeutics' current patient assistance resources directly. Cigna's coordination-of-benefits policy generally prohibits using manufacturer coupons when the drug is covered under any plan tier, but when Cigna explicitly denies coverage, coupon use is permissible for the cash-pay transaction.

HSA and FSA Eligibility

Enclomiphene prescribed for a diagnosed medical condition (secondary hypogonadism with documented lab values) qualifies as an HSA/FSA-eligible expense under IRS Publication 502 rules. Keep the prescription and diagnosis code (ICD-10 E23.0 for hypogonadotropic hypogonadism) on file for account documentation.

What Prescribers Should Know: Writing the Prescription to Maximize Coverage

The way the prescription is written affects PA approval rates.

Diagnosis Code Selection

Use ICD-10 code E23.0 (Hypogonadotropic hypogonadism) rather than the broader E29.1 (Testicular hypofunction). E23.0 maps directly to the secondary-hypogonadism pattern that Cigna's medical policy references and reduces the chance of a coding mismatch that triggers automatic denial.

Dosing Alignment

The FDA-approved dosing for Androxal is 12.5 mg or 25 mg orally once daily. PA requests for doses outside this range (for example, 50 mg, which some clinicians prescribe off-label) give Cigna reviewers an additional reason to deny. Submit PAs at 12.5 mg or 25 mg daily unless there is a documented clinical reason for a different dose, in which case explain it explicitly.

Prescriber Specialty

Cigna PA reviewers give greater weight to prescriptions from urologists, reproductive endocrinologists, or endocrinologists than from primary care physicians for specialty endocrine drugs. If the patient's primary care physician is prescribing enclomiphene, a co-signature or referral note from a specialist strengthens the PA.

The Endocrine Society's 2018 guideline states directly: "We recommend confirming the diagnosis of androgen deficiency before initiating treatment and monitoring patients on testosterone therapy to ensure that treatment goals are being met." (Bhasin et al., J Clin Endocrinol Metab, 2018) That language supports the argument that diagnosis confirmation with LH/FSH data is standard of care, not an optional step.

Enclomiphene vs. Clomiphene Citrate: Why the Distinction Matters for Insurance

Cigna formularies often carry generic clomiphene citrate (the racemic mixture) as a Tier 1 or Tier 2 drug for off-label male hypogonadism. Clomiphene is the racemic mixture of the zuclomiphene (cis) and enclomiphene (trans) isomers. Enclomiphene is the pharmacologically active isomer for LH stimulation, while zuclomiphene has a much longer half-life and may contribute to estrogenic side effects.

A head-to-head comparison in a 2013 study showed that enclomiphene raised testosterone to a greater degree per milligram than clomiphene citrate at equivalent doses, with a more favorable testosterone-to-estradiol ratio (Wiehle et al., Int J Androl, 2013). If a patient has already tried clomiphene and experienced inadequate testosterone normalization or elevated estradiol, that trial serves as direct step-therapy evidence for the PA.

Document specifically: the clomiphene dose used, duration (minimum 60 days is generally acceptable), the testosterone value achieved, and any adverse effects. That documentation converts a potential step-therapy obstacle into a step-therapy completion, moving the PA toward approval.

Quick Reference: Cigna Enclomiphene PA Checklist

Use this before submitting any PA to Cigna for enclomiphene citrate.

• Two morning testosterone draws below 300 ng/dL, at least one week apart: included.
• LH and FSH results showing hypogonadotropic pattern: included.
• ICD-10 code E23.0 on all claim documents: confirmed.
• Dose requested matches FDA-approved range (12.5 mg or 25 mg daily): confirmed.
• Clinical letter from prescribing physician referencing Endocrine Society 2018 guideline: included.
• Step-therapy documentation (prior clomiphene or TRT trial, or fertility-preservation override): included.
• Compounded vs. Branded status clarified: confirmed.
• Plan type confirmed (fully insured vs. Self-insured employer): confirmed.